The fight against cancer is at an all-time high. This deadly disease can manifest from many vital organs within the body. Cancer research is also at an all-time high, and it is producing medications that are very effective for fighting this disease. One of the biggest and best cancer research institutions in the world is known as Seattle Genetics. This company has been around since the late 1990s, and it has made huge progress in this demanding sector of business. Dr. Clay Siegall is the company’s CEO and president. He has provided the proper leadership and guidance that is needed to operate such a brilliant machine. The company has done so well over the past few years that its stock has roughly tripled.
Dr. Siegall is the man with the plan, and he uses this plan to save lives. How does he do it? Seattle Genetics produces the top cancer fighting medications in the world. Anti-body Drug Conjugates are designed to seek out and to destroy cancerous cells within the human body. These medications gives cancerous cells a powerful death blow, which eradicates it. Another great feature of (ADCs) is that they aren’t as harsh as previous medications like chemotherapy. The side effects of chemotherapy can make the patient feel as sick as the disease itself. Dr. Siegall is shaking up the industry because his company has many more advanced medications already in the pipeline. Its current premium drug ADCETRIS, has a multiple license deal with other major pharmaceutical giants like Pfizer and GlaxoSmithKline. This deal is actually a license agreement, and with this agreement, the medications can be distributed throughout the world. There’s no wonder why the companies stock has risen so high.
Dr. Siegall is one of the most trusted individuals of this industry, and his passion to save lives can be felt. He is simply focused on the task at hand. By having so much cutting-edge technology on deck, Seattle Genetics doesn’t look to be slowing down anytime soon.
Dr. Clay B. Siegall is an entrepreneur and a medical specialist who is actively taking part in the fight against cancer. Dr. Clay Siegall is an owner of a wee-established medical research company which is based in Seattle – Seattle Genetics. It was formed in 1998 and has made many contributions to the medical community in its years of operation.
Seattle Genetics was created out of the desire of Dr. Clay Siegall to save or at least improve the lives of patients who have any type of cancer. His own father had died of cancer which made Dr. Clay Siegall very aware of the little oncologists can do for people like his father. The company of Seattle Genetics was established in order to develop medication as well as technology which oncologists will be able to use.
One of the contributions made by Seattle Genetics is the brentuximab vedotin drug with the name of ADCETRIS®. This medication had been approved in 2011 and had been distributed all around the world. Up to date, ADCETRIS® is a medication that is available to cancer patients in more than seventy countries. The are a total of 15 patents that Dr. Clay Siegall is the owner of. Some of them have also been approved by the FDA, and some are pending.
Dr. Clay Siegall majored in Zoology from the University of Maryland, and after that, he pursued a degree in Genetics. He earned his Ph. D. in genetics from the George Washington University. After he had completed his education, Dr. Clay Siegall made the first steps towards joining the fight against cancer. He began to do research at the esteemed Bristol-Myers Squibb Pharmaceutical Research Institute where he worked at two positions. After a few years, he moved on and started living in new York City. In New York City, Dr. Clay Siegall continued his research further as a part of the nation Institute of health.
Dr. Clay Siegall has been striving to contribute to the medical community his whole career, and he is most proud of his company Seatle Genetics which has been very successful so far.